Cipla celebrates 90 years with focus on quality products, global presence, and investment in research and technology.

Cipla faces revenue and margin pressure due to the upcoming Revlimid patent expiry, leading to underperformance and analyst ...

Mumbai-headquartered drugmaker Cipla Ltd is bolstering its focus on a pipeline of drugs to fight infections caused by ...

Shanghai: Indian pharmaceutical giant Cipla is exploring entry into at least two new international markets for products ...

Common flu, seasonal throat infections, and fevers are on the rise in India, making it imperative to practice every day self-care and community protection. Leading the charge, Cipla Health Ltd., one ...

The Indian pharmaceutical industry is likely to benefit from a major wave of patent expiries in the US, as small-molecule ...

The healthcare sector, particularly pharmaceuticals and hospitals, have demonstrated strong performance in the March 2025 quarter, with revenue growth exceeding that of Nifty 500 companies. Even ...

In this guest post, Rajesh Radhakrishnan explores how brands are using phygital activations at Pandharpur Yatra 2025 to drive ...

Linda Jónsdóttir, Alvotech's Chief Financial Officer ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the expansion of its capacity for ...

The Business Research Company's Asthma and COPD Drugs Market 2025: Strategic Insights for Growth, Expansion, and Gaining Competitive Edge It will grow to $50.99 billion in 2029 at a compound annual ...